Idiopathic minimal-change disease (MCD) is the most common nephrotic syndrome in children and adolescents. 1 The disease is considered a disorder of T cell function. 2, 3 Although the mechanism of the proteinuria is unknown, a circulating cytokine has been postulated as the link between proteinuria and the T cell dysfunction. [2] [3] [4] Podocytes are specialized and highly differentiated epithelial cells that form a layer between the glomerular basement membrane and the urinary space. In a series of experiments, Reiser et al. 5 found that these cells could acquire dendritic cell-like functions, in which they can be induced to express CD80, a transmembrane protein that provides a co-stimulatory signal for T cell activation. Mice administered LPS developed podocyte CD80 expression and proteinuria; when LPS was administered to the CD80 Ϫ/Ϫ knockout mouse, no increase in urinary protein excretion was observed. 5 The authors further showed that podocyte CD80 activation by LPS could occur in SCID mice that lack T cells. 5 Furthermore, CD80 expression could be shown in both experimental models of nephrotic syndrome (e.g., aminonucleoside nephrosis) and human lupus nephritis. 5 These findings led the authors to propose that podocyte CD80 expression might be involved in the pathogenesis of MCD. 6 Some podocyte antigens are known to be shed, where they can be found in the urine. 7 This led us to hypothesize that soluble CD80 (sCD80) might be detected in the urine in patients with MCD. Furthermore, T regulatory cells are known to secrete soluble CTLA-4 (sCTLA-4), which can bind CD80 and block the costimulatory activation of T cells. 8 -10 If T cells are releasing a cytokine that can induce MCD, such as IL-13, 11 then one might postulate that an inadequate release of sCTLA-4 might lead to continued activation of the T cells and possibly persistent CD80 expression by dendritic cells. We therefore measured urinary sCD80 and urinary sCTLA-4 levels in children with MCD and compared the findings with healthy children and children with other glomerular diseases.
Clinical characteristics of the patients with MCD and control groups are shown in Table 1 . We measured urinary sCD80 excretion adjusted for urinary creatinine in patients with MCD (n ϭ 19), patients with other glomerular diseases (n ϭ 11), and normal control subjects (n ϭ 9; Figure  1A ). Urinary sCD80 excretion was elevated in patients with MCD in relapse compared with patients with MCD in remission (P Ͻ 0.001), patients with other glomerular diseases (P Ͻ 0.001), and healthy control subjects (P Ͻ 0.01).
When we studied eight patients with MCD during relapse off immunosuppressive therapy and 1 mo after remission was induced, the differences were still marked (P Ͻ 0.01; Figure 1B ). In four patients with MCD, we measured urine CD80 excretion during various stages of their nephrotic syndrome. In these patients, changes in proteinuria were paralleled by changes in urinary sCD80 excretion ( Figure 1C ). Urinary sCD80 was not significantly elevated in healthy control subjects or in patients with nephrotic syndrome and other glomerular diseases when compared with patients with MCD in remission ( Figure  1A ). In patients with MCD in relapse, there was no correlation between sCD80 and proteinuria ( Figure 2 ).
Serum sCD80
In contrast with the urinary findings, serum sCD80 concentrations were not different among patients with MCD in re- lapse, patients with MCD in remission, and normal control subjects (307 Ϯ 78, 297 Ϯ 58, and 374 Ϯ 28, pg/ml, mean Ϯ SEM, respectively).
Urinary sCD80 and sCTLA-4
In a separate study, we examined concomitant urine sCD80 and sCTLA-4 concentrations during relapse and during early remission on therapy in patients with MCD. Results are presented in Figure 3A . As in our previous study, urinary sCD80 was significantly increased during relapse when compared with values measured during remission (P Ͻ 0.009). Urinary sCTLA-4 concentrations in patients in relapse were not statistically significant to those observed in patients in remission (P ϭ 0.25). When the ratio of urinary sCD80 to sCTLA-4 was evaluated in patients with MCD, the ratio changed from 10.80 Ϯ 6.10 during relapse to 0.10 Ϯ 0.05 during remission (mean Ϯ SEM; P Ͻ 0.008; Figure 3B ). In contrast, the same ratio in patients with FSGS and proliferative glomerulonephritis and nephrotic syndrome was 0.66 Ϯ 0.28 (mean Ϯ SEM).
Serum sCTLA-4
Serum sCTLA-4 levels in patients with MCD in relapse (376 Ϯ 174 pg/ml, mean Ϯ SEM; n ϭ 8) were not statistically different from the values observed for patients in remission (229 Ϯ 86 pg/ ml; n ϭ 9). No significant difference in serum sCD80/sCTLA-4 ratio between relapse and remission was observed (1.8 Ϯ 0.6 [n ϭ 8] and 6.1 Ϯ 5.1 [n ϭ 7], mean Ϯ SEM, respectively).
Urinary CD80 in Systemic Lupus Erythematosus
Urinary CD80 levels in patients with systemic lupus erythematosus (SLE) without proteinuria (urinary protein-creatinine ratio Ͻ0.5; 111 Ϯ 34 ng/mg creatinine, mean Ϯ SEM; n ϭ 13) were not statistically different from those observed for patients with proteinuria (136 Ϯ 65 ng/mg creatinine, mean Ϯ SEM; n ϭ 8; P ϭ 0.96). Urinary CD80 values including all patients with SLE (127 Ϯ 31 ng/mg creatinine, mean Ϯ SEM) were significantly lower than those observed for patients with MCD in relapse (P ϭ 0.0001) but not significantly different from those seen in patients with MCD in remission and healthy control subjects. CD80 is a dendritic-associated receptor that mediates co-stimulatory signaling of the T cell. Expression of CD80 on podocytes was demonstrated by Reiser et al. 5, 6 in several experimental models of glomerular disease associated with nephrotic syndrome. Similarly, CD80 was been reported to be expressed on podocytes in human lupus nephritis. 5 In this study, we demonstrated that urinary sCD80 was elevated in MCD during relapse with levels returning to the normal range in remission. Furthermore, serial studies showed that the urinary sCD80 excretion paralleled changes in proteinuria in four of the patients. The increase in urinary sCD80 was not simply a reflection of proteinuria per se, because it was not observed in patients who had proteinuria and/or nephrotic syndrome and had other glomerular dis- eases. In addition, serum sCD80 levels were not different for patients with MCD in relapse from patients with MCD in remission and normal control subjects, documenting that the increased urinary excretion could not be accounted for by higher serum levels.
Patients with lupus nephritis and proteinuria have been reported to have CD80 expression on their podocytes. 5 Despite this observation, we did not find urinary sCD80 levels to be increased in patients with SLE and proteinuria. Indeed, levels of sCD80 in the urine were not different from those observed in healthy control subjects and in patients with MCD in remission. In addition, sCD80 urinary excretion in patients with SLE was significantly lower than that seen in patients with MCD in relapse; however, some of our patients with SLE and with or without concomitant proteinuria did have increased urinary sCD80 excretion. Urinary sCD80 levels are difficult to interpret in patients with SLE because these patients have been reported to have elevated serum sCD80 levels unrelated to the activity of the disease. 12 Because sCD80 has a molecular weight of 23 kD, the increased urinary sCD80 seen in some of our patients with SLE could be due to higher serum sCD80 values.
The co-stimulatory activation of T cells can be blocked by sCTLA-4 released by T regulatory cells, 8 -10 and sCTLA-4 may also negatively regulate the CD80-bearing dendritic cell. 9 This led us to hypothesize that sCTLA-4 might be reduced in patients with MCD in relapse. Although we detected no statistically significant differences in serum or urinary CTLA-4 between patients with MCD in relapse and in remission, we did observe that the ratio of urinary sCD80 to sCTLA-4 was markedly higher in patients with MCD in relapse compared with remission. The relative decrease in urinary sCTLA-4 to sCD80 during relapse could be due to the inability of the T regulatory cells from patients with MCD to release sCTLA-4. We recently demonstrated that T regulatory cells are normal in number but severely dysfunctional in patients with MCD in relapse. 13 More studies are needed to confirm our hypothesis that this defect could result in uncontrolled CD80 podocyte activation with persistent proteinuria.
This pilot study raises several interesting questions. First, it raises the possibility that urinary sCD80 levels may be helpful in the diagnosis of patients with MCD. Although larger patient populations will be necessary to study before concluding that this test may be specific for MCD, it is interesting that none of the four patients with FSGS and nephroticrange proteinuria had elevated sCD80 levels. Second, it raises the question of the source of the CD80. Theoretically, a number of cells within the kidney could produce CD80, including podocytes, macrophages, dendritic cells, and tubular cells. 5, 14, 15 If the podocyte is the source expressing CD80, then it could be relevant to the pathogenesis of the disease. In this regard, we were recently able to demonstrate CD80 expression in a few biopsies of patients with MCD in relapse (unpublished observations).
In conclusion, urinary sCD80 is increased in patients with MCD in relapse and seems to correlate with the activity of the disease. Further studies to examine the role of urinary sCD80 as a diagnostic, pathogenic, and prognostic marker are indicated as well as to determine the role, if any, that sCTLA-4 has in this process.
CONCISE METHODS

Patients
The study was approved by the institutional review board of the University of Florida, and written informed consent was obtained before participation. Children and adolescents with biopsy-proven MCD (n ϭ 19), defined according to the International Study for Kidney Diseases in Children, were studied. 16 The majority of patients with MCD during relapse and during remission were receiving variable amounts of immunosuppressive therapy. Control subjects (n ϭ 9) included a group of age-and gender-matched healthy children and adolescents. None of the normal control subjects included in the study had any underlying immunologic disorder. In addition, we examined patients with FSGS (n ϭ 4), membranoproliferative glomerulonephritis (n ϭ 2), membranous nephropathy (n ϭ 3), IgA nephropathy (n ϭ 2), and SLE (n ϭ 21). Definitions of glomerular diseases were based on established criteria according to the International Study for Kidney Diseases in Children. 16 
Methods
Relapse of the nephrotic syndrome was defined as the presence of proteinuria of Ն3ϩ using the tetrabromophenol-citrate buffer colorimetric qualitative dipstick test, confirmed by a urine protein/creatinine ratio Ͼ2.0, and a concomitant serum albumin of Ͻ3.5 g/L during the course of the episode. Complete remission was defined as no proteinuria using the colorimetric qualitative test and a urinary protein/creatinine ratio of Ͻ0.2 on a random urine sample.
We measured sCD80 in blood and urine using a commercially available ELISA kit (Bender MedSystems, Burlingame, CA). We measured sCTLA-4 in blood and urine according to Oaks and Hallet 10 with minor modifications. We measured urinary creatinine and proteinuria using an autoanalyzer.
Statistical Analysis
We conducted statistical analysis using nonparametric ANOVA (Kruskal-Wallis test). We determined differences between means with the Mann-Whitney U test or the Wilcoxon signed rank test when applicable. We calculated the correlation between urinary sCD80 and urinary protein using Spearman's correlation coefficient test.
